Negative Pressure Wound Therapy (for New Mexico Only)

Coverage Summary

Scope: This policy (Policy Number CS157NM.C, Effective Date 2026-06-01) governs UnitedHealthcare New Mexico coverage for Negative Pressure Wound Therapy (NPWT), limited to the state of New Mexico and focused on outpatient use or discharge from inpatient settings. The policy addresses proven/medically necessary outpatient indications, unproven/not medically necessary uses, contraindications, discontinuation criteria, documentation requirements, and applicable procedure and device codes.

Subject and payer: The subject is Negative Pressure Wound Therapy (NPWT) in the outpatient/discharge setting. Payer guidance is UnitedHealthcare New Mexico; geographic applicability is limited to New Mexico. Coverage stance at a high level is mixed — certain outpatient indications are defined as proven/medically necessary while other indications and device types are specified as unproven or not medically necessary. The policy emphasizes medical record documentation requirements for reviews and potential prior authorization.

Quick facts & selected thresholds

Conventional treatment trial duration30 days (documentation that open wound has not responded after 30 days required prior to NPWT)

Compression therapy duration (venous ulcers)Compression bandages/garments used consistently for at least 30 days

Wound depth for discontinuationDepth <= 1 mm (stop NPWT when wound depth is 1 mm or less)

BMI threshold citedBMI >= 35 kg/m2 (NICE: consider NPWT after cesarean birth for women with BMI 35 or more)

Diabetic foot wound improvement threshold> 50% wound area reduction after minimum 4 weeks of standard therapy before adjunctive modalities considered

RCT counts (Cochrane update)62 RCTs (Cochrane review update totaling 62 RCTs)

Individuals in Cochrane review13,340 individuals (total included in the 62 RCTs)

Medical-Necessity Criteria

General prerequisite: Complete wound therapy program

A complete wound therapy program must have been tried or considered and ruled out prior to initiation of NPWT. Documentation must show all of the following elements.

ref

title

ref_temp_removed

ref_fixed

ref_fixed_value_was_invalid_make_valid_again_replaced_with_ref_field_b1_0

Coding

Covered/Referenced CPT codes for NPWT sessionsCPTCovered

97605	NPWT utilizing DME per session; total wound(s) surface area <= 50 sq cm
97606	NPWT utilizing DME per session; total wound(s) surface area > 50 sq cm
97607	NPWT utilizing disposable, non-durable medical equipment per session; total wound(s) surface area <= 50 sq cm
97608	NPWT utilizing disposable, non-durable medical equipment per session; total wound(s) surface area > 50 sq cm

Covered/Referenced HCPCS / DME supply codesHCPCSCovered

A6550	Wound care set for negative pressure wound therapy electrical pump, includes all supplies and accessories
A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each
E2402	Negative pressure wound therapy electrical pump, stationary or portable

Other device codes noted (clarification)HCPCS

K0743-K0746

Suction pumps and dressing codes apply to devices other than NPWT (coding clarification noted in policy)

Provider Actions & Documentation Requirements

Documentation Required

Complete wound therapy documentation required

Providers must document a complete wound therapy evaluation and ongoing clinical monitoring to support use of NPWT. Documentation should include the items below to demonstrate prior conservative care, device selection, and clinical response over time.

Evaluation and care notes describing wound assessment and plan
Wound measurements (length, width, depth) and description of wound bed (granulation, slough, eschar)
Trial of moist wound dressings and other conventional therapy prior to NPWT initiation
Dates and descriptions of any debridement procedures (surgical, enzymatic, or autolytic)
Nutritional assessment and interventions to address deficits
Provider statement of the indication for NPWT and rationale linking to prior therapies
Documentation that the open wound has not responded to conventional treatment after 30 days
Documentation of high-risk features or prior standard therapy tried (e.g., peripheral arterial disease, neuropathy, infection history, prior graft or flap, prior compression/offloading)

Background, Evidence, and Definitions

Background: Negative Pressure Wound Therapy (NPWT), also called vacuum-assisted wound closure, applies subatmospheric pressure to a wound via a sealed dressing connected by tubing to a suction pump and collection chamber to remove exudate and promote granulation, reduce edema, and approximate wound edges as an adjunct when wounds do not respond to conventional care. This policy applies only to New Mexico and is focused on outpatient use or initiation on discharge from inpatient settings.

Device types: The policy distinguishes device types and approaches, including single-use NPWT (s-NPWT), traditional reusable/tank-based NPWT, and NPWT with instillation and dwell time (NPWTi-d), as well as closed-incision or incisional NPWT (ciNPWT / iNPWT); evidence and coverage positions differ by device type and indication.

Source	Key point
Cochrane review (pressure ulcers)	Very low certainty; efficacy of NPWT for pressure ulcers is uncertain due to small trials, limited data on complete healing and adverse events
Kirsner et al. (2019)	s-NPWT was superior to traditional NPWT for wound size reduction and closure (ITT and per-protocol; p≤0.003), but compared NPWT types, not against standard dressings
Wang et al. (2022) meta-analysis (diabetic foot ulcers)	Significant improvements in healing metrics and lower amputation risk with NPWT vs moist wound care (reduced nonclosure risk, more granulation, lower amputation RR 0.70)
Cochrane (2022) update (surgical incisions)	Across 62 RCTs (13,340 individuals) NPWT probably results in fewer surgical site infections than standard dressings; no difference in wound dehiscence (moderate certainty)
Hayes assessments (2023-2025)	Conclude insufficient or low-quality evidence for routine NPWT use in closed incisions after hip/knee arthroplasty and pilonidal disease; call for further RCTs
IWGDF (2024)	Conditional recommendation to consider NPWT for postsurgical diabetic foot wounds (low quality); recommend against NPWT for nonsurgical diabetic foot ulcers
WHS (2024)	NPWT safe and effective for chronic stage III/IV pressure ulcers (level I); may be useful for venous/arterial ulcers in certain contexts
NPWTi-d systematic reviews/meta-analyses	Multiple small/heterogeneous studies suggest faster wound closure and fewer debridements vs NPWT or standard care, but overall evidence low-quality and heterogeneous; more RCTs needed
NICE guidance (various)	VAC Veraflo and ciNPWT show promise in specific settings (e.g., high-risk closed incisions, cesarean with BMI≥35) but evidence not sufficient for routine adoption; consider after debridement for diabetic foot ulcers
Cochrane review (pressure ulcers, Shi et al. 2023)	Updated review found low-certainty evidence from small RCTs; efficacy, safety, and acceptability of NPWT for pressure ulcers remain uncertain
NPWT for pilonidal disease (systematic reviews and RCTs)	Evidence very low quality and inconsistent; recent RCTs show no clear benefit—insufficient to support routine use
Open surgical wounds / abdominal surgery (Polomska et al. 2025)	Some meta-analyses show reduced surgical site infection with NPWT vs primary closure, but heterogeneity and low certainty limit conclusions; larger RCTs needed
Sahin et al. (2021)	Small RCT showed NPWT effective vs wet-to-dry dressing for stage III/IV pressure injuries (significant granulation and wound shrinkage) but limited by small sample and short follow-up
Hayes evidence on chronic wounds/home use	Reports describe potential benefits (healing, shorter time to closure) but note low-quality evidence and potential harms; updated reviews call for more data
Venous ulcer studies (SPACE, Ulloa et al. 2025)	Single-arm or limited studies report significant wound-size reduction and good safety profile with NPWT, but single-center and small sample limit generalizability
Open fractures (Alves 2024; WOLFF/WHIST trials)	Some meta-analyses suggest lower infection rates with NPWT for Gustilo III fractures; large RCTs (WOLLF/WHIST) show mixed results and no clear long-term functional benefit
Cochrane review (open traumatic wounds, Iheozor-Ejiofor 2018)	Moderate-certainty evidence for no clear difference in proportion healed at 6 weeks for open fractures; uncertain effect on infection and other outcomes
Closed incisions - systematic reviews/meta-analyses (Feier, Mantyh, SUNRRISE, SUNRRISE/SUNRRISE trial)	Some meta-analyses show reduced superficial SSI with ciNPWT in select surgeries, but recent large RCTs (SUNRRISE, SUNRRISE group) do not support routine use for all indications
ECRI / cesarean obesity evidence	Evidence suggests NPWT reduces SSI in obese women after cesarean in some meta-analyses; recommendation is to consider in high-risk (BMI≥35) patients
Hayes reviews on prophylactic NPWT for abdominal surgery and cesarean/TKA/hip arthroplasty	Conclude low-quality, inconsistent evidence with uncertain clinical importance; advise more RCTs before routine adoption
Pilonidal disease systematic reviews (Morais 2025) and RCT (Ensor 2024)	Meta-analyses show very low-certainty signals (possible shorter healing) but RCTs find no benefit for dehiscence or healing endpoints—evidence insufficient

Gustilo Grade III Fracture: An open fracture with extensive soft tissue damage or an open segmental fracture. Subtypes: IIIA = adequate soft tissue coverage despite extensive laceration or high-energy trauma; IIIB = extensive soft tissue loss with periosteal stripping and bone exposure often requiring soft-tissue coverage; IIIC = arterial injury requiring repair.

Stage III Pressure Injury (NPIAP): Full-thickness loss of skin in which fat may be visible; fascia, muscle, tendon, ligament, cartilage, or bone are not exposed; undermining/tunneling may occur.

Stage IV Pressure Injury (NPIAP): Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone.

NPWTi-d: Negative Pressure Wound Therapy with instillation and dwell time — instillation of solution into the wound followed by negative pressure.

ciNPWT / iNPWT: Closed/incisional negative pressure wound therapy applied over closed surgical incisions.

Revision History

06/01/2026addedLatest

Documentation must include relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures; must be legible and available upon request. Added language clarifying medical records documentation used for reviews and that documentation may be required to assess whether the member meets clinical criteria for coverage.

revised

Multiple bibliographic entries and references were updated/added. Updated Clinical Evidence and References sections to reflect the most current information.

archived